Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
KING OF PRUSSIA, Pa., March 29, 2017 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will be presenting at Needham & Company’s 16th Annual Healthcare Conference on Wednesday, April 5, 2017 at 10:00 a.m. EDT in New York.
To join a live audio webcast of the presentation, please visit the Investor section of the Company’s website. Following the conclusion of the presentation, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company developing innovative therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. The Company has discovered four novel and differentiated drug candidates, including OLINVO™ (oliceridine injection). Trevena also has discovered TRV250, in preclinical development for the treatment of migraine, and TRV734, for pain. The Company is actively working on an early stage portfolio of drug discovery programs.
Contacts Trevena, Inc. Investors: Jonathan Violin, Ph.D. Sr. Director, Investor Relations 610-354-8840 x231 [email protected] or Media: Public Relations [email protected]
